Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

A Sphingosine-1-Phosphate Receptor 1-Directed Agonist Reduces Central Nervous System Inflammation in a Plasmacytoid Dendritic Cell-Dependent Manner.
Neuro-Ophthalmic Syndromes and Processing Speed in Multiple Sclerosis.
Early P2X7R-related astrogliosis in autoimmune encephalomyelitis.
Management of multiple sclerosis in adolescents - current treatment options and related adherence issues.
Randomized controlled trial of physical activity, cognition, and walking in multiple sclerosis.
Cerebrospinal Fluid IL-21 Levels in Neuromyelitis Optica and Multiple Sclerosis.
Anti-high mobility group box 1 monoclonal antibody ameliorates experimental autoimmune encephalomyelitis.
NLRP3 Inflammasome and MS/EAE.
Response to Letter to the Editor 'Simvastatin improves final visual outcome in acute optic neuritis, a randomized study'
Current status of chemokines in the adult CNS.
Recent achievements in stem cell-mediated myelin repair.
A genome-wide association meta-analysis of self-reported allergy identifies shared and allergy-specific susceptibility loci.
Remission of Severe Myasthenia Gravis After Massive-Dose Vitamin D Treatment.
A basic overview of multiple sclerosis immunopathology.
Transcriptional de-repression of ERVWE1 following influenza A virus infection.
Biochemical markers of neurodegeneration in hereditary diffuse leucoencephalopathy with spheroids.
Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients.
Astrogliosis During Acute and Chronic Cuprizone Demyelination and Implications for Remyelination.
Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse.
Reduced Myelin Water in the White Matter Tracts of Patients with Niemann-Pick Disease Type C.
Does Lipoic Acid Consumption Affect the Cytokine Profile in Multiple Sclerosis Patients: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Biomarkers of Therapeutic Response in Multiple Sclerosis: Current Status.
Novartis MS pill heads stream of SMC approvals
Available evidence and outcome of off-label use of rituximab in clinical practice.
Multiple Sclerosis: Current Knowledge and Future Outlook.

Pages